Possible discontinuation of treatment by tyrosine kinase inhibitors in patients with chronic myeloid leukemia and concept of treatment-free remission
Authors:
J. Šrámek; M. Karas; D. Lysák; P. Jindra
Authors‘ workplace:
Hematologicko-onkologické oddělení, Fakultní nemocnice Plzeň
Published in:
Transfuze Hematol. dnes,23, 2017, No. 4, p. 192-198.
Category:
Overview
Implementation of tyrosine kinase inhibitors (TKI) into the therapy of chronic myeloid leukemia (CML) represented an important milestone in hematologic and oncologic targeted therapy. Imatinib dramatically improved prognosis of pa-
tients with CML, which now represents a chronic disease, with the need of livelong therapy. Many patients achieve deep molecular response during the therapy with TKI, and there is an increasing number of studies presenting the possibility of save cessation of TKI therapy. Long-term usage of TKI increases the probability of side effects of the therapy. This manuscript will present current knowledge about discontinuation of TKI therapy in patients with CML, overview of results of selected clinical studies and present approach to probable mechanisms and pathophysiology of treatment-free remission.
Key words:
chronic myeloid leukemia – CML – treatment-free remission – TFR – imatinib – tyrosine kinase inhibitors – TKI
Sources
1. O’Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11): 994–1004.
2. Cortes EJ, Saglio G, Kantarjian HM, et al. Final 5-year study results of dASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016;34: 2333–2340.
3. Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia; publikováno elektronicky 14. srpna 2017; DOI: 10.1038/leu.2017.253.
4. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122: 872–884.
5. Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118: 4554–4560.
6. Branford S, Seymour JF, Grigg A, et al. BCRABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007;13(23): 7080–7085.
7. Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 2013;122(5): 641–647.
8. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002;20: 214–220.
9. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109: 58–60.
10. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11: 1029–1035.
11. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122: 515–522.
12. Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011;121: 396–409.
13. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32: 424–430.
14. Saußele S, Richter J, Hochhaus A, Mahon FX. The concept of treat-ment-free remission in chronic myeloid leukemia. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30(8): 1638–1647.
15. Mahon FX, Richter J, Guilhot J, et al. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial. Blood 2016;128(22): Abstract 787.
16. Hughes TP, Ross DM. Moving treatment-free remission into main-stream clinical practice in CML. Blood 2016;128(1): 17–23.
17. Imagawa J, Tanaka H, Okada M, et al. DADI Trial Group. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015;2(12): e528–e535.
18. Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 2017;129: 846–854.
19. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011;118: 3657–3660.
20. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011;118: 5565–5572.
21. Ilander MM, Olsson-Stromberg U, Lahteenmaki H, et al. Early disease relapse after tyrosine kinase inhibitor treatment discontinuation in CML is related both to low number and impaired function of NK-cells. Blood 2014;124(21): Abstract 812.
22. Rea D, Dulphy N, Henry G, et al. Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from immunostim, on behalf of STIM Investigators. Blood 2013;122(21): Abstract 856.
23. Hughes A, Clarson J, Tang C, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 2017;129(9): 1166–1176.
24. Takashi K, Chiaki N, Kaichi N, et al. Discontinuation of dasatinib after deep molecular response for over 2 years in patients with chronic myelogenous leukemia and the unique profiles of lymphocyte subsets for successful discontinuation: a prospective, multicenter Japanese trial (D-STOP Trial). Blood 2016;128(22): Abstract 791.
25. University of Jena. Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dostupné na www: https://clinicaltrials.gov/ct2/show/NCT01657604 NLM Identifier: NCT01657604; 2014.
26. Burchert A, Saussele S, Eigendorff E, et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia 2015;29: 1331–1335.
27. Pagliardini T, Nicolini FE, Giraudier S, et al. Second TKI discontinua-tion in CML patients that failed first discontinuation and subsequently regained deep molecular response after TKI re-challenge. Blood 2016;128(22): Abstract 788.
28. Goldberg S, Hamarman S. Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy. Blood 2015:126(23): Abstract 1584.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2017 Issue 4
Most read in this issue
- Angioimmunoblastic T-lymphoma: overview, single centre experience and case report of the sequential development of difuse large B-cell lymphoma
- Next generation sequencing in acute myeloid leukaemia: new insights into the pathogenesis and development of leukemic clones
- Possible discontinuation of treatment by tyrosine kinase inhibitors in patients with chronic myeloid leukemia and concept of treatment-free remission
- The first oral proteasome inhibitor in the treatment of relapsed/refractory multiple myeloma